# LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

> **NCT05990465** · PHASE1 · RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 12 (estimated)

## Conditions studied

- Non Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma
- Burkitt Lymphoma

## Interventions

- **DRUG:** Pirtobrutinib
- **DRUG:** LV20.19 CAR T cells

## Key facts

- **NCT ID:** NCT05990465
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-06
- **Primary completion:** 2026-07
- **Final completion:** 2027-07
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05990465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05990465, "LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05990465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*